Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The study is a Phase 1 Open-label Two-stage, Safety and Tolerability Study with Cancer
Type-specific Cohorts, Evaluating Subcutaneous Administration of Andes-1537 for Injection in
Patients with Advanced Solid Tumors that are Refractory to Standard Therapy or For Which No
Standard Therapy Is Available. Patients with unresectable solid tumors that are refractory or
have failed standard therapy and are deemed non-eligible or intolerant to further therapy or
for which no standard therapy is available will be included in 5 cancer type-specific
parallel cohorts. The following tumor types will be evaluated for potential inclusion in each
cancer type-specific cohort: gallbladder & biliary tract carcinoma; cervical carcinoma;
gastric carcinoma; pancreatic carcinoma, and colorectal carcinoma.